ERBB2 and breast carcinoma: Therefore, future clinical trials should involve the integration of novel anti-breast cancer stem cells approaches to prevent and overcome the inherent unresponsiveness to trastuzumab across clinically important subgroups of HER2-positive breast cancer patients.